YIFAN PHARMACEUTICAL(SZ:002019)2022-12-06 23:58Group 1: Company Overview - Yifan Xinfu Pharmaceutical Co., Ltd. is actively engaging with institutional investors to discuss various aspects of its business [2] - The company is led by Chairman and General Manager Cheng Xianfeng, along with other key executives [2] Group 2: Product and Market Insights - The price of the company's product, calcium pantothenate, remains stable and is expected to rise for Q3 orders [3] - The acquisition of DHY Company has been completed, and ongoing projects are progressing as planned, with F627 entering Phase III clinical trials in 40 centers across 13 countries [3][4] Group 3: Financial Activities - The company plans to issue non-public A-shares, pending approval from the China Securities Regulatory Commission, with a target issuance within six months after receiving the approval [4] - Multiple institutions have expressed interest in participating in the upcoming share issuance [4] Group 4: Business Development and Strategy - The company aims to maintain steady growth in its original business while integrating new acquisitions, with two newly established subsidiaries already obtaining GMP certification [4][5] - The company is adapting to industry changes such as the "two-invoice system" and "VAT reform," viewing these as opportunities for compliant and legal operations [5] Group 5: Healthcare Sector Engagement - Yifan Xinfu is cautiously entering the healthcare sector through partnerships, having successfully signed contracts with two managed hospitals [5]